Published on December 1, 2009 at 6:55 AM
US-based pharmaceutical company Radient Pharmaceuticals Corporation (NYSE Amex: RPC) announced today the following update to its press release dated Monday, November 30, 2009 and entitled "Radient Pharma Completes Registered Direct Offering For Approximately $1 Million."
The press release originally stated the amount of the placement agent fees associated with the stated registered direct offering. As the exclusive placement agent for the transaction, Jesup & Lamont Securities Corporation will receive a cash fee equal to 6% of the gross proceeds of the offering, a non-accountable expense allowance equal to (a) 2% of the gross proceeds of the offering less (b) the actual amount of accountable expenses paid to or on behalf of Jesup & Lamont on or prior to the closing, and will receive warrants equal to 2% of the shares of common stock purchased by the investors in the offering.
SOURCE: Radient Pharmaceuticals Corporation
c957f39f-5ef2-42a2-b159-2ce072b5e80f|0|.0
Posted in: